RDS
MCID: RSP019
MIFTS: 52

Respiratory Distress Syndrome in Premature Infants (RDS)

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Respiratory Distress Syndrome in Premature Infants

MalaCards integrated aliases for Respiratory Distress Syndrome in Premature Infants:

Name: Respiratory Distress Syndrome in Premature Infants 57 72 29
Hyaline Membrane Disease 58 72 70
Infant Acute Respiratory Distress Syndrome 58
Neonatal Respiratory Distress Syndrome 58
Respiratory Distress Syndrome, Newborn 70
Infant Respiratory Distress Syndrome 58
Hyaline Membrane Disease, Formerly 57
Rds of Prematurity 57
Rds in Prematurity 72
Infant Ards 58
Rds 72

Characteristics:

Orphanet epidemiological data:

58
infant acute respiratory distress syndrome
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
isolated cases
multifactorial

Miscellaneous:
onset at birth
may be associated with polymorphisms in some surfactant genes, including sftpa1 , sftpb , and sftpc


HPO:

31
respiratory distress syndrome in premature infants:
Inheritance multifactorial inheritance sporadic
Onset and clinical course congenital onset


Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

OMIM® 57 267450
MeSH 44 D006819
ICD10 via Orphanet 33 P22.0
UMLS via Orphanet 71 C0020192 C0035220 C0852283
Orphanet 58 ORPHA70587
MedGen 41 C1968593
UMLS 70 C0020192 C0035220

Summaries for Respiratory Distress Syndrome in Premature Infants

OMIM® : 57 The main cause of respiratory distress syndrome (RDS) in premature infants is a developmental deficiency of pulmonary surfactant. The frequency of RDS is inversely proportional to gestational age. However, not all infants born prematurely develop RDS, suggesting that there may be susceptibility factors. Because multiple factors can contribute to the pathogenesis of RDS specifically in premature infants, the etiology is considered to be multifactorial (summaries by Ramet et al., 2000; Clark and Clark, 2005). Pathogenic germline mutations in several genes involved in surfactant metabolism, including SFTPB (178640) and SFTPC (178620), can cause clinical features of respiratory distress syndrome in term neonates, children, and adults, disorders referred to as 'surfactant metabolism dysfunction' (see, e.g., SMDP1, 265120). Susceptibility to the development of RDS in premature infants may be associated with polymorphisms in surfactant genes, such as surfactant protein A1 (SFTPA1; 178630), SFTPB, and SFTPC (see MOLECULAR GENETICS). (267450) (Updated 05-Apr-2021)

MalaCards based summary : Respiratory Distress Syndrome in Premature Infants, also known as hyaline membrane disease, is related to respiratory distress syndrome, infant and pneumonia, and has symptoms including dyspnea, hemoptysis and apnea. An important gene associated with Respiratory Distress Syndrome in Premature Infants is SFTPB (Surfactant Protein B), and among its related pathways/superpathways are Metabolism of proteins and Diseases of metabolism. The drugs Zinc and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include lung, fetal lung and bone marrow, and related phenotypes are hypoxemia and atelectasis

UniProtKB/Swiss-Prot : 72 Respiratory distress syndrome in premature infants: A lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high- permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'.

Wikipedia : 73 Infantile respiratory distress syndrome (IRDS), also called respiratory distress syndrome of newborn, or... more...

Related Diseases for Respiratory Distress Syndrome in Premature Infants

Diseases related to Respiratory Distress Syndrome in Premature Infants via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 respiratory distress syndrome, infant 31.8 SFTPC ABCA3
2 pneumonia 30.0 SFTPC SFTPB
3 meconium aspiration syndrome 29.6 SFTPB ABCA3
4 respiratory failure 29.5 SFTPC SFTPB ABCA3
5 adult respiratory distress syndrome 29.3 SFTPC SFTPB ABCA3
6 newborn respiratory distress syndrome 29.3 SFTPC SFTPB SFTPA1 ABCA3
7 pulmonary fibrosis, idiopathic 29.1 SFTPC SFTPB SFTPA1 ABCA3
8 pulmonary interstitial emphysema 29.0 SFTPC SFTPB SFTPA1 ABCA3
9 neonatal respiratory failure 28.9 SFTPC SFTPB ABCA3
10 surfactant dysfunction 28.8 SFTPC SFTPB SFTPA1 ABCA3
11 pulmonary immaturity 28.7 SFTPC SFTPB SFTPA1 ABCA3
12 lung disease 28.6 SFTPC SFTPB SFTPA1 ABCA3
13 choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction 11.7
14 choroidal dystrophy, central areolar, 1 11.0
15 collagen vi-related dystrophies 10.9
16 retinal degeneration 10.8
17 retinitis pigmentosa 10.7
18 neuroretinitis 10.7
19 retinitis 10.7
20 bronchopulmonary dysplasia 10.6
21 pneumothorax 10.5
22 retinal disease 10.5
23 patent ductus arteriosus 1 10.4
24 macular degeneration, age-related, 1 10.4
25 pattern dystrophy 10.4
26 pre-eclampsia 10.3
27 cone-rod dystrophy 2 10.3
28 retinitis pigmentosa 7 10.3
29 fundus dystrophy 10.3
30 inherited retinal disorder 10.3
31 butterfly-shaped pigment dystrophy 10.3
32 macular dystrophy, patterned, 1 10.2
33 gestational diabetes 10.2
34 primary interstitial lung disease specific to childhood due to pulmonary surfactant protein anomalies 10.2
35 choroidal dystrophy, central areolar 2 10.2
36 disseminated intravascular coagulation 10.2
37 pulmonary edema 10.2
38 alcohol dependence 10.2
39 macular dystrophy, vitelliform, 3 10.2
40 vitelliform macular dystrophy 10.2
41 enterocolitis 10.2
42 perinatal necrotizing enterocolitis 10.2
43 exudative vitreoretinopathy 1 10.1
44 cardiac arrest 10.1
45 rickets 10.1
46 periventricular leukomalacia 10.1
47 otitis media 10.1
48 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
49 preterm premature rupture of the membranes 10.1
50 funisitis 10.1

Graphical network of the top 20 diseases related to Respiratory Distress Syndrome in Premature Infants:



Diseases related to Respiratory Distress Syndrome in Premature Infants

Symptoms & Phenotypes for Respiratory Distress Syndrome in Premature Infants

Human phenotypes related to Respiratory Distress Syndrome in Premature Infants:

58 31 (show all 20)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypoxemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0012418
2 atelectasis 58 31 frequent (33%) Frequent (79-30%) HP:0100750
3 premature birth 58 31 frequent (33%) Frequent (79-30%) HP:0001622
4 respiratory failure 58 31 frequent (33%) Frequent (79-30%) HP:0002878
5 tachypnea 58 31 frequent (33%) Frequent (79-30%) HP:0002789
6 cyanosis 58 31 frequent (33%) Frequent (79-30%) HP:0000961
7 pulmonary edema 58 31 frequent (33%) Frequent (79-30%) HP:0100598
8 nasal flaring 58 31 frequent (33%) Frequent (79-30%) HP:0030863
9 abnormal thorax morphology 31 frequent (33%) HP:0000765
10 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
11 tachycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001649
12 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
13 cardiac arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0001695
14 bradycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001662
15 sepsis 58 31 very rare (1%) Very rare (<4-1%) HP:0100806
16 neonatal respiratory distress 31 HP:0002643
17 abnormality of the thorax 58 Frequent (79-30%)
18 respiratory distress 31 HP:0002098
19 respiratory tract infection 58 Occasional (29-5%)
20 disseminated intravascular coagulation 31 HP:0005521

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Respiratory:
dyspnea
tachypnea
respiratory insufficiency, neonatal

Prenatal Manifestations Delivery:
premature delivery, less than 37 weeks' gestation

Respiratory Lung:
atelectasis
decreased surfactant
lung edema
fibrin-rich alveolar deposits, 'hyaline membranes'
diffuse reticulogranular pattern seen on chest radiograph

Clinical features from OMIM®:

267450 (Updated 05-Apr-2021)

UMLS symptoms related to Respiratory Distress Syndrome in Premature Infants:


dyspnea; hemoptysis; apnea; respiratory distress; cheyne-stokes respiration; coughing; hoarseness

MGI Mouse Phenotypes related to Respiratory Distress Syndrome in Premature Infants:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 8.92 ABCA3 SFTPA1 SFTPB SFTPC

Drugs & Therapeutics for Respiratory Distress Syndrome in Premature Infants

Drugs for Respiratory Distress Syndrome in Premature Infants (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5
Racepinephrine Approved Phase 4 329-65-7 838
6
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
7
Cisatracurium Approved Phase 4 96946-41-7 62887
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
15 Poractant alfa Approved Phase 4 129069-19-8
16
Remifentanil Approved Phase 4 132875-61-7 60815
17
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
18
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Budesonide Approved Phase 4 51333-22-3 63006 5281004
22
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
23 Carotenoids Phase 4
24 Chelating Agents Phase 4
25 Iron Chelating Agents Phase 4
26
Picolinic acid Phase 4 98-98-6 1018
27 Provitamins Phase 4
28 Cholinergic Agents Phase 4
29 Hydrocortisone hemisuccinate Phase 4
30 Cholinergic Antagonists Phase 4
31 Hydrocortisone 17-butyrate 21-propionate Phase 4
32 Epinephryl borate Phase 4
33 Neuromuscular Blocking Agents Phase 4
34 Psychotropic Drugs Phase 4
35 GABA Modulators Phase 4
36 Anti-Anxiety Agents Phase 4
37 Neuromuscular Nondepolarizing Agents Phase 4
38 Excitatory Amino Acid Antagonists Phase 4
39 Anesthetics, Dissociative Phase 4
40 Anesthetics Phase 4
41 Anesthetics, General Phase 4
42 Anesthetics, Intravenous Phase 4
43 Analgesics, Opioid Phase 4
44 Angiotensin Receptor Antagonists Phase 4
45 Platelet Aggregation Inhibitors Phase 4
46 Antihypertensive Agents Phase 4
47
Glycopyrrolate Phase 4 596-51-0 3494
48 Angiotensin II Type 1 Receptor Blockers Phase 4
49 Tin Fluorides Phase 4
50 Anesthetics, Inhalation Phase 4

Interventional clinical trials:

(show top 50) (show all 936)
# Name Status NCT ID Phase Drugs
1 Efficacy Evaluation of Surfactant Administration for Respiratory Distress Syndrome Treatment Via Laryngeal Mask Airway. A Randomized Controlled Trial Unknown status NCT01173237 Phase 4
2 Efficacy of Rescue Surfactant Delivery Via Endotracheal Intubation (INSURE Technique) Versus Laryngeal Mask Airway (LMA) for Respiratory Distress Syndrome (RDS) in Preterm Neonates Unknown status NCT02164734 Phase 4 remifentanil
3 The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates Unknown status NCT03366584 Phase 4 Dexamethasone
4 Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT01763853 Phase 4 4% albumin
5 The Effect of Maternal Antenatal Steroid Administration on the Blood Flow Through the Pulmonary Artery in the Term Fetus; a Randomized Control Double Blinded Study Unknown status NCT02978976 Phase 4 Betamethasone;saline
6 Comparative Trial of Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams Unknown status NCT00277030 Phase 4 Surfactant
7 Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI) Unknown status NCT00368680 Phase 4
8 Sleep Intervention During Acute Lung Injury Unknown status NCT01050699 Phase 4 Dexmedetomidine;Midazolam and Fentanyl
9 Propofol and Remifentanil Versus Midazolam and Remifentanil as Premedication Allowing Very Early Extubation After Surfactant Treatment in Preterm Neonates With Respiratory Distress Syndrome Unknown status NCT00797160 Phase 4 propofol
10 Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS Unknown status NCT01573715 Phase 4 NIMBEX;NIMBEX
11 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
12 Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study Unknown status NCT03275415 Phase 4 budesonide;Saline
13 THE EFFECT OF SUSTAINED LUNG INFLATION MANEUVER APPLIED THROUGH NASAL PRONG ON EARLY AND LATE RESPIRATORY MORBIDITIES IN PRETERM INFANTS Unknown status NCT02887924 Phase 4
14 Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency Unknown status NCT00773058 Phase 4 hydrocortisone;placebo
15 An International, Open, Randomized, Controlled Study to Evaluate the Efficacy of Combining Prophylactic Curosurf® With Early Nasal CPAP Versus Early Nasal CPAP Alone in Very Preterm Infants at Risk of Respiratory Distress Syndrome Completed NCT00501982 Phase 4 Poractant alfa (Curosurf®)
16 Rescue Surfactant for Respiratory Distress Syndrome (RDS) in Newborns: Comparing Efficacy of Delivery Via Laryngeal Mask Airway to Delivery by Endotracheal Intubation Completed NCT01042600 Phase 4
17 Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress Completed NCT00486850 Phase 4
18 Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant Completed NCT01941524 Phase 4 Poractant alfa instillation;Beractant instillation
19 Effects of Bolus Surfactant Therapy on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants With Severe Respiratory Distress Syndrome Completed NCT01923844 Phase 4 exogenous surfactant
20 Comparative Study of the Use of Remifentanil Versus Morphine for Sedation and Analgesia of Premature Neonates During Mechanical Ventilation in the Treatment of Respiratory Distress Syndrome (RDS) Completed NCT00391105 Phase 4 Remifentanil
21 Corticosteroid Mediates Acute Respiratory Distress Syndrome Via NLRP3 Inflammasome Signaling Pathway Completed NCT02819453 Phase 4 Methylprednisolone
22 Effects Of A Recruitment Maneuver On Plasma Levels of sRAGE, The Soluble Form of The Receptor For Advanced Glycation End Products, In Patients With Diffuse Acute Respiratory Distress Syndrome (ARDS) Completed NCT01600651 Phase 4
23 Effect of Early 48-hour Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients Presenting With Acute Respiratory Distress Syndrome (ARDS) : a Monocentric, Prospective, Randomized Study. Completed NCT02166853 Phase 4 sevoflurane;midazolam
24 Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants Completed NCT01741129 Phase 4
25 Premedication for Non-Emergency Endotracheal Intubation In the NICU Completed NCT01749501 Phase 4 Rocuronium
26 A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome Completed NCT01731795 Phase 4 Dexamethasone
27 The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients Completed NCT03337373 Phase 4 cisatracurium
28 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Recruiting NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
29 Premedication for Less Invasive Surfactant Administration Recruiting NCT03735563 Phase 4 Ketamine;Fentanyl
30 PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease Recruiting NCT04335786 Phase 4 Valsartan (Diovan);Placebo oral tablet
31 Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial Recruiting NCT04334629 Phase 4 Ibuprofen
32 Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection Recruiting NCT04359862 Phase 4 Sevoflurane;Propofol
33 Effect of Inhalation Sedation With Sevoflurane Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome (ARDS) Course. Recruiting NCT04014218 Phase 4 Inhalation Sedation;Intravenous Sedation
34 Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
35 Role of Prophylactic Dexamethasone Administration Before Elective Cesarean Section at Term in Reducing the Incidence of Neonatal Respiratory Distress Syndrome (A Randomized Controlled Trial) Not yet recruiting NCT04816097 Phase 4 Dexamethasone phosphate
36 Stress Assessment in Preterm Infants With Respiratory Distress Syndrome Treated or Not With an Analgesic Drug During the Traditional or the Less Invasive Method of Surfactant Therapy. Not yet recruiting NCT04073173 Phase 4 Analgesic, Opioid
37 The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients Not yet recruiting NCT04345887 Phase 4 Spironolactone 100mg;Placebo oral tablet
38 Comparison of Two Fraction Oxygen Inspired (FiO2) Thresholds for the Surfactant Administration in Preterm Infants With Respiratory Disease Syndrome: a Single-center Randomized Phase IV Clinical Trial Not yet recruiting NCT04199364 Phase 4 Poractant Alfa 80 mg/mL Intratracheal Suspension
39 Effects of Adding L-Carnitine With Dexamethasone on Respiratory Distress Syndrome Development in Preterm Infants Suspended NCT03630367 Phase 4 Dexamethasone;L-Carnitine 1G/5mL Injection
40 Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial) Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
41 Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants Terminated NCT00146497 Phase 4 Budesonide-Surfactant
42 Randomized Study Comparing the ASV to Conventional Ventilation for Intubated Patients During Inter-hospital Transfers. Controlled Randomized Monocentric Prospective Study Comparing ASV Versus Conventional Ventilation Modes Terminated NCT02348047 Phase 4
43 Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome. Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
44 Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 Terminated NCT04325061 Phase 4 Dexamethasone
45 Pre Hospital Evaluation of Video Laryngoscopy : a Comparative Study of Macintosh and GLIDESCOPE Ranger® Withdrawn NCT01374061 Phase 4
46 Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome Unknown status NCT01265589 Phase 3 surfactant;surfactant+vitamin A
47 A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients Unknown status NCT00465374 Phase 3
48 Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial Unknown status NCT02774044 Phase 2, Phase 3 Cadisurf;Survanta
49 Liberal Oxygenation Versus Conservative Oxygenation in Patients With Acute Respiratory Distress Syndrome : Impact on Mortality (LOCO2 Study) Unknown status NCT02713451 Phase 3 Modulation of Inspired Fraction of Oxygen (FiO2)
50 Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room. Unknown status NCT01517828 Phase 3 Sedation by ketamine;Sedation with Midazolam

Search NIH Clinical Center for Respiratory Distress Syndrome in Premature Infants

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Albumin Human, USP
ALBUMIN,AGGREGATED
ALBUMIN,EGG
ALBUMIN,HUMAN INJ
ALBUMIN,MICROSPHERE HUMAN SERUM
beractant
Colfosceril
colfosceril palmitate
Nitric Oxide
Poractant alfa

Genetic Tests for Respiratory Distress Syndrome in Premature Infants

Genetic tests related to Respiratory Distress Syndrome in Premature Infants:

# Genetic test Affiliating Genes
1 Respiratory Distress Syndrome in Premature Infants 29

Anatomical Context for Respiratory Distress Syndrome in Premature Infants

MalaCards organs/tissues related to Respiratory Distress Syndrome in Premature Infants:

40
Lung, Fetal Lung, Bone Marrow, Bone, Neutrophil, Heart, Liver

Publications for Respiratory Distress Syndrome in Premature Infants

Articles related to Respiratory Distress Syndrome in Premature Infants:

(show top 50) (show all 1741)
# Title Authors PMID Year
1
The genetics of neonatal respiratory disease. 57
15927881 2005
2
Surfactant protein C gene variation in the Finnish population - association with perinatal respiratory disease. 57
14735158 2004
3
Surfactant protein B polymorphism and respiratory distress syndrome in premature twins. 57
12483294 2003
4
Surfactant proteins A and B as interactive genetic determinants of neonatal respiratory distress syndrome. 57
11063734 2000
5
Association between the surfactant protein A (SP-A) gene locus and respiratory-distress syndrome in the Finnish population. 57
10762543 2000
6
Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome. 57
7952631 1994
7
Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. 57
1741552 1991
8
Respiratory-distress syndrome and disseminated intravascular coagulation in two siblings. 57
4108940 1972
9
Outcomes of newborns to mothers with COVID-19. 61
33748807 2021
10
Tension pneumocephalus, an uncommon complication of oxygen therapy in preterm newborns. Presentation of a case and literature review. 61
31784352 2021
11
Maternal and Perinatal Factors Associated With Twin Pregnancies in Ecuador. 61
33752776 2021
12
Analysis of Pathology in Premature Infants in Obstetrics and Gynecology Clinic at St George University Hospital, Plovdiv between 2013 and 2015. 61
33650401 2021
13
Surfactant dysfunction disorder masquerading as meconium aspiration syndrome and persistent pulmonary hypertension of the newborn. 61
33504532 2021
14
Optimal delivery timing for twin pregnancies: A population-based retrospective cohort study. 61
33420725 2021
15
The burden of hyaline membrane disease, mortality and its determinant factors among preterm neonates admitted at Debre Tabor General Hospital, North Central Ethiopia: A retrospective follow up study. 61
33784349 2021
16
Comparison of Long Term Follow-up Chest CT Imaging in Adult and Pediatric Patients with Humidifier Disinfectant-related Lung Injury. 61
33230985 2020
17
A survey on criteria for intubation in moderate to late preterm infants with respiratory distress. 61
32886426 2020
18
Bovine or Porcine: Does the Type of Surfactant Matter? 61
32112649 2020
19
Novel homozygous missense mutation in ABCA3 protein leading to severe respiratory distress in term infant. 61
33040033 2020
20
Extrauterine growth restriction in very preterm infant: etiology, diagnosis, and 2-year follow-up. 61
32193657 2020
21
Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure. 61
32275979 2020
22
Neuroendoscopic lavage for the management of posthemorrhagic hydrocephalus in preterm infants: safety, effectivity, and lessons learned. 61
32413865 2020
23
Vitamin D deficiency and its effect on respiratory distress syndrome in premature infants: results from a prospective study in a tertiary care centre. 61
33402932 2020
24
Effects of less invasive surfactant administration (LISA) via a gastric tube on the treatment of respiratory distress syndrome in premature infants aged 32 to 36 weeks. 61
32118723 2020
25
50 Years Ago in TheJournalofPediatrics: Intermittent Positive Pressure Ventilation in Hyaline Membrane Disease. 61
32040408 2020
26
50 Years Ago in TheJournalofPediatrics: Commentary: The Use of Assisted Ventilation in the Therapy of Hyaline Membrane Disease. 61
32040409 2020
27
Etiology, clinical profile and outcome of neonatal pneumothorax in tertiary care center in South India: 13 years experience. 61
32075452 2020
28
Risk Factors of Respiratory Diseases Among Neonates in Neonatal Intensive Care Unit of Qena University Hospital, Egypt. 61
32140431 2020
29
The influence of maternal ethnicity on neonatal respiratory outcome. 61
31123055 2020
30
Minimally Invasive Tissue Sampling in Preterm Deaths: A Validation Study. 61
32923527 2020
31
Comparison of the detection rates for retinopathy of prematurity (ROP) of the 2013 Philippine Academy of Ophthalmology (PAO) Revised Philippine Guidelines and the 2005 PAO-Philippine Pediatric Society (PPS) Guidelines for ROP screening in the Philippine General Hospital: a 5-year review. 61
33094166 2020
32
Fetal, neonatal, and infant death in central China (Hubei): A 16-year retrospective study of forensic autopsy cases. 61
31169678 2019
33
Outcome of Respiratory Distress in Neonates with Bubble CPAP at Neonatal Intensive Care Unit of a Tertiary Hospital. 61
31477940 2019
34
Predictors of Neonatal mortality in Neonatal intensive care unit at referral Hospital in Southern Ethiopia: a retrospective cohort study. 61
30819143 2019
35
Growth restriction increases the risk of bronchopulmonary dysplasia, death, and sepsis in twins of 30 weeks or less of gestation. 61
31095217 2019
36
Survival and predictors among preterm neonates admitted at University of Gondar comprehensive specialized hospital neonatal intensive care unit, Northwest Ethiopia. 61
30616641 2019
37
Case report of a laryngotracheal reconstruction with anterior and posterior costal cartilage graft and stent placement - Surgical technique. 61
31039513 2019
38
Co-initiation of continuous renal replacement therapy, peritoneal dialysis, and extracorporeal membrane oxygenation in neonatal life-threatening hyaline membrane disease: A case report. 61
30681590 2019
39
Phospholipid components of the synthetic pulmonary surfactant CHF5633 probed by fluorescence spectroscopy. 61
30366070 2018
40
Hyaline membrane disease (HMD): an historical and Oslerian perspective. 61
30291319 2018
41
Proportion and factors of death among preterm neonates admitted in University of Gondar comprehensive specialized hospital neonatal intensive care unit, Northwest Ethiopia. 61
30522518 2018
42
An autopsy based descriptive study of the spectrum of pulmonary lesions encountered in fetal deaths at a tertiary care center. 61
30303136 2018
43
Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. 61
30289565 2018
44
Outcomes of self-induced late pregnancy termination in women presenting to a tertiary hospital in the Eastern Cape Province, South Africa. 61
30645966 2018
45
A pre-term infant of 32 weeks gestation with congenital tuberculosis treated successfully with antituberculosis chemotherapy. 61
28805143 2018
46
A study of spectrum of pulmonary pathology and expression of thyroid transcription factor-1 during neonatal period. 61
30004050 2018
47
Scenario of Neonatal Respiratory Distress in Tertiary Hospital. 61
29983424 2018
48
Clinicoetiological Pattern and Outcome of Neonates Requiring Mechanical Ventilation: Study in a Tertiary Care Centre. 61
29910548 2018
49
Neonatal respiratory distress syndrome and underlying mechanisms in cloned cattle. 61
29388718 2018
50
Pulmonary atelectasis in newborns with clinically treatable diseases who are on mechanical ventilation: clinical and radiological aspects. 61
29559762 2018

Variations for Respiratory Distress Syndrome in Premature Infants

Expression for Respiratory Distress Syndrome in Premature Infants

Search GEO for disease gene expression data for Respiratory Distress Syndrome in Premature Infants.

Pathways for Respiratory Distress Syndrome in Premature Infants

Pathways related to Respiratory Distress Syndrome in Premature Infants according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 SFTPC SFTPB SFTPA1 ABCA3
2
Show member pathways
11.3 SFTPC SFTPB SFTPA1
3 11.06 SFTPC SFTPA1
4
Show member pathways
10.56 SFTPC SFTPB SFTPA1 ABCA3
5
Show member pathways
10.53 SFTPC SFTPB SFTPA1

GO Terms for Respiratory Distress Syndrome in Premature Infants

Cellular components related to Respiratory Distress Syndrome in Premature Infants according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.67 SFTPC SFTPB SFTPA1 ABCA3
2 endoplasmic reticulum membrane GO:0005789 9.58 SFTPC SFTPB SFTPA1
3 clathrin-coated endocytic vesicle GO:0045334 9.33 SFTPC SFTPB SFTPA1
4 multivesicular body GO:0005771 9.32 SFTPB SFTPA1
5 multivesicular body lumen GO:0097486 9.26 SFTPC SFTPB
6 lamellar body GO:0042599 9.13 SFTPC SFTPB SFTPA1
7 alveolar lamellar body GO:0097208 8.8 SFTPC SFTPB ABCA3

Biological processes related to Respiratory Distress Syndrome in Premature Infants according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid transport GO:0006869 9.16 SFTPA1 ABCA3
2 respiratory gaseous exchange GO:0007585 9.13 SFTPC SFTPB SFTPA1
3 cellular protein metabolic process GO:0044267 8.92 SFTPC SFTPB SFTPA1 ABCA3

Molecular functions related to Respiratory Distress Syndrome in Premature Infants according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid transporter activity GO:0005319 8.62 SFTPA1 ABCA3

Sources for Respiratory Distress Syndrome in Premature Infants

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....